NSCLC is among the first cancers that benefited from immune checkpoint inhibitors (ICI), especially monoclonal antibodies blocking the programmed death-1/programmed death ligand-1 axis (anti-PD-1/PD-L1), with profound and durable responses in some cases [4,5]. Here, CD274 is linked to non-small cell lung carcinoma.